BAD, BCL2 associated agonist of cell death, 572

N. diseases: 125; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.080 Biomarker group BEFREE OGD/R-mediated DNA fragmentation and Casp3 expression could be prevented as well as resolved by the addition of hWJ-MSC-derived EV before and after OGD, respectively. hWJ-MSC-derived EV also tended to increase the phosphorylation of the B cell lymphoma 2 (Bcl2) family member Bcl-2-antagonist of cell death (BAD) in N2a cells, when added prior or post OGD, thereby inactivating the proapoptotic function of BAD. 29562785 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.080 AlteredExpression group BEFREE Anti-apoptosis B-cell lymphoma (Bcl)-2 and Bcl-w genes were downregulated and pro-apoptotic Bcl-2-associated agonist of cell death and caspase-3 genes were upregulated in U-2OS cells following treatment with β-elemene-paclitaxel. 30008912 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.080 Biomarker group BEFREE The apoptosis‑associated signaling showed that ursolic acid decreased the phosphorylation of AKT (Ser473) and B‑cell lymphoma 2 (Bcl‑2)‑associated agonist of cell death (BAD; Ser136), and the protein levels of Bcl‑2 and Bcl‑extra large (Bcl‑xL), and increased the expression of BAD and Bcl‑2‑associated X (Bax) protein in CAR cells. 29956797 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.080 GeneticVariation group BEFREE Western blot analysis was performed in order to determine the differential expression levels of Janus kinase (JAK), signal transducer and activator of transcription 3 (STAT3) and apoptosis associated proteins B-cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein (Bax) and Bcl-2 associated agonist of cell death (Bad). 28599489 2017
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.080 AlteredExpression group BEFREE Apoptosis was triggered through the intrinsic pathway by upregulating the expression of several B-cell lymphoma-2 (Bcl-2) family proapoptotic proteins, including p53-upregulated modulator of apoptosis (PUMA), Bcl-2-associated X protein and Bcl-2-associated agonist of cell death, and by downregulating the antiapoptotic protein Bcl-extra large. 28529565 2017
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.080 Biomarker group BEFREE In addition to increased B-cell lymphoma 2 (Bcl-2) phosphorylation through JNK signaling in response to docetaxel, si-Vav3 enhanced docetaxel-induced apoptosis, as characterized by the accumulation of sub-G1 phase cells and DNA fragmentation, through Bcl-xL/Bcl-2-associated death promoter (Bad) dephosphorylation, resulting in increased caspase-9, caspase-3, and cleaved poly(ADP-ribose) polymerase activation. 23566222 2013
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.080 Biomarker group LHGDN BCL10 gene amplification associated with strong nuclear BCL10 expression in a diffuse large B cell lymphoma with IGH-BCL2 fusion. 16785131 2006
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.080 GeneticVariation group BEFREE We conclude that mutations in the BAD gene do not play a role in the pathogenesis of the major subtypes of human B-cell lymphomas. 16646081 2006